Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ULK1 | O75385 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708499 | 1.00 | HPGD (0.58) | HPGDPOLBULK1SCN3AGAA | |
| Hydrochloric Acid SCHEMBL3266984 | 0.98 | HPGD (0.57) | HPGDPOLBULK1SCN3AGAA | |
| SCHEMBL9352214 | 0.95 | HPGD (0.56) | HPGDPOLBULK1SCN3AGAA | |
| SCHEMBL2392383 | 0.95 | HPGD (0.56) | HPGDPOLBULK1SCN3AGAA | |
| SCHEMBL2172641 | 0.95 | HPGD (0.56) | HPGDPOLBULK1SCN3AGAA | |
| Hydrochloric Acid SCHEMBL4306381 | 0.94 | SCN3A (0.56) | HPGDPOLBULK1SCN3AGAA | |
| SCHEMBL7072829 | 0.90 | HPGD (0.56) | HPGDPOLBGAAMAPTDPP4 | |
| SCHEMBL7072835 | 0.90 | HPGD (0.56) | HPGDPOLBGAAMAPTDPP4 | |
| SCHEMBL1752153 | 0.86 | SCN3A (0.59) | HPGDULK1SCN3AMAPTSCN9A | |
| SCHEMBL17676961 | 0.86 | SCN3A (0.59) | HPGDULK1SCN3AMAPTSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102093284-B | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2013-05-08 | — | — | CN | claimed |
| CN-102093284-A | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2011-06-15 | — | — | CN | claimed |
| US-5786484-A | Racemization and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof | CHIROSCIENCE LIMITED (GB) | 1998-07-28 | — | — | US | claimed |
| CN-1168134-A | Racemization process for the production of levobupivacaine and related piperidinecarboxanilide anaesthetics | CHIROSCIENCE LTD (GB) | 1997-12-17 | — | — | CN | claimed |
| EP-0804417-A1 | RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS | Chiroscience Limited (GB) | 1997-11-05 | — | — | EP | claimed |
| EP-0782569-A1 | RACEMISATION AND ASYMMETRIC TRANSFORMATION PROCESSES USED IN THE MANUFACTURE OF LEVOBUPIVACAINE AND ANALOGUES THEREOF | CHIROSCIENCE LIMITED (GB) | 1997-07-09 | — | — | EP | claimed |
| WO-1996022281-A1 | RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS | CHIROSCIENCE LIMITED (GB) | 1996-07-25 | — | — | WO | claimed |
| WO-1996009290-A1 | RACEMISATION AND ASYMMETRIC TRANSFORMATION PROCESSES USED IN THE MANUFACTURE OF LEVOBUPIVACAINE AND ANALOGUES THEREOF | CHIROSCIENCE LIMITED (GB) | 1996-03-28 | — | — | WO | claimed |
| EP-2068958-B1 | MEDICAL DEVICE INCLUDING AN ANESTHETIC AND METHOD OF PREPARATION THEREOF | COOK MEDICAL TECHNOLOGIES LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| CN-102093284-B | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-102093284-B | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-102093284-B | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2013-05-08 | — | — | CN | disclosed |
| US-20120027819-A1 | Medical Devices Incorporating a Bioactive and Methods of Preparing Such Devices | ISCH ANDREW P (US) | 2012-02-02 | — | — | US | disclosed |
| CN-102093284-A | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2011-06-15 | — | — | CN | disclosed |
| WO-1996022281-A1 | RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS | CHIROSCIENCE LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996011181-A1 | THE MANUFACTURE OF LEVOBUPIVACAINE AND ANALOGUES THEREOF FROM L-LYSINE | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996009290-A1 | RACEMISATION AND ASYMMETRIC TRANSFORMATION PROCESSES USED IN THE MANUFACTURE OF LEVOBUPIVACAINE AND ANALOGUES THEREOF | CHIROSCIENCE LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996009290-A1 | RACEMISATION AND ASYMMETRIC TRANSFORMATION PROCESSES USED IN THE MANUFACTURE OF LEVOBUPIVACAINE AND ANALOGUES THEREOF | CHIROSCIENCE LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0674644-A1 | HERBICIDAL IMIDAZOLONES AND A PROCESS FOR THEIR MANUFACTURE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995010277-A1 | ANALGESIC AGENT AND ITS USE | CHIROSCIENCE LIMITED (GB) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027819-A1 | Medical Devices Incorporating a Bioactive and Methods of Preparing Such Devices | ATP6V1B1, ASIC1, FGF23 | HPGD 459/4885POLB 3776/4885ULK1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.